Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Shandong Pharmaceutical Glass Co Company

600529.SS
CNE000001BG9

Price

29.12
Today +/-
+0.22
Today %
+6.05 %
P

Shandong Pharmaceutical Glass Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Shandong Pharmaceutical Glass Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Shandong Pharmaceutical Glass Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Shandong Pharmaceutical Glass Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Shandong Pharmaceutical Glass Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Shandong Pharmaceutical Glass Co Stock Price History

DateShandong Pharmaceutical Glass Co Price
9/30/202429.12 undefined
9/27/202427.41 undefined
9/26/202426.50 undefined
9/25/202425.54 undefined
9/24/202425.50 undefined
9/23/202425.04 undefined
9/20/202425.03 undefined
9/19/202424.89 undefined
9/18/202424.72 undefined
9/13/202424.27 undefined
9/12/202424.56 undefined
9/11/202425.19 undefined
9/10/202424.75 undefined
9/9/202424.82 undefined

Shandong Pharmaceutical Glass Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Shandong Pharmaceutical Glass Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shandong Pharmaceutical Glass Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shandong Pharmaceutical Glass Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shandong Pharmaceutical Glass Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shandong Pharmaceutical Glass Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shandong Pharmaceutical Glass Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shandong Pharmaceutical Glass Co’s growth potential.

Shandong Pharmaceutical Glass Co Revenue, EBIT and net profit per share

DateShandong Pharmaceutical Glass Co RevenueShandong Pharmaceutical Glass Co EBITShandong Pharmaceutical Glass Co Net Income
2026e7.15 B undefined1.4 B undefined1.37 B undefined
2025e6.43 B undefined1.27 B undefined1.19 B undefined
2024e5.68 B undefined1.09 B undefined1.01 B undefined
20234.98 B undefined855.24 M undefined775.8 M undefined
20224.19 B undefined671.79 M undefined618.29 M undefined
20213.88 B undefined692.35 M undefined591.09 M undefined
20203.43 B undefined671.7 M undefined564.4 M undefined
20192.99 B undefined532.3 M undefined458.7 M undefined
20182.58 B undefined410 M undefined358.2 M undefined
20172.33 B undefined310.9 M undefined262.8 M undefined
20162.06 B undefined267.5 M undefined189.6 M undefined
20151.72 B undefined205.8 M undefined145.4 M undefined
20141.69 B undefined171.5 M undefined124.7 M undefined
20131.54 B undefined175.8 M undefined122.3 M undefined
20121.47 B undefined163.9 M undefined119.8 M undefined
20111.4 B undefined145.6 M undefined132.5 M undefined
20101.51 B undefined207.2 M undefined171.3 M undefined
20091.24 B undefined178.7 M undefined144.4 M undefined
20081.16 B undefined147.1 M undefined135.2 M undefined
20071.01 B undefined164.9 M undefined114.7 M undefined
2006855.8 M undefined152.2 M undefined96.1 M undefined
2005672.1 M undefined131.2 M undefined82.5 M undefined
2004560.2 M undefined118.8 M undefined75.7 M undefined

Shandong Pharmaceutical Glass Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.230.290.350.420.470.560.670.861.011.161.241.511.41.471.541.691.722.062.332.582.993.433.884.194.985.686.437.15
-26.8419.4520.5710.9019.6620.0027.2318.3614.437.2521.82-7.675.085.189.521.8919.3813.2710.9015.7914.5413.078.0518.9913.9913.2211.12
36.3633.4536.0036.4937.8236.9633.9331.8129.2527.8930.2729.2826.9126.6326.9425.9630.4731.5031.6735.0636.4332.6828.9026.2727.44---
0.080.10.130.150.180.210.230.270.30.320.380.440.380.390.420.440.530.650.740.911.091.121.121.11.37000
0.050.050.070.090.10.120.130.150.160.150.180.210.150.160.180.170.210.270.310.410.530.670.690.670.861.091.271.4
20.7817.0619.1420.6222.0121.0719.4917.7816.2112.6914.3313.6810.3811.1011.3310.1111.9012.9813.3015.8717.7819.5817.8616.0317.1619.1219.6919.61
0.030.030.040.050.070.080.080.10.110.140.140.170.130.120.120.120.150.190.260.360.460.560.590.620.781.011.191.37
-7.1423.3345.9529.637.149.3317.0718.7518.426.6718.75-22.81-9.852.521.6416.9430.3438.6236.6427.9323.144.794.5725.4029.8118.3914.78
----------------------------
----------------------------
266.8266.8266.8436.1436.1436.1436.1436.1493.1504.5504.5504.5504.5504.5504.5504.5504.5502.2595595595595594.97663.61663.61000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Shandong Pharmaceutical Glass Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Shandong Pharmaceutical Glass Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                 
0.030.030.050.420.180.090.120.090.160.090.220.220.190.130.180.290.41.261.441.51.391.241.022.262.5
92.392.585.285.6112.9163.1209.1250.4284.7315338373.9330.8374.2407.3424.1390.7436.2388.5383.5405.2640.8764.36871.66970.12
22.835.738.552.284.7145.7159216.6235.2222.9283.3296.7234.5319.1319.9305.8290.1253.8336.1353.4333.9307.9438.93698.74763.78
0.070.080.080.070.080.130.170.210.210.30.290.330.40.450.490.470.530.510.550.570.680.750.881.211.05
7.56.114.812.724.141.76090.4130.5132.8142.42429357.524.927.72243.138.2179.1199.7205.6239.03278.76252.29
0.220.240.270.640.480.570.720.861.021.061.271.471.241.331.421.531.632.52.752.9933.143.345.325.55
0.130.140.180.290.540.650.680.650.750.830.860.971.111.151.161.161.21.241.291.451.972.242.843.173.48
0.10.20.10.10.12.616.789.247.244.23129.840.233.12626.224.922.30.10.10.10.10.050.050.05
0000000000000000000000000
6.97.576.810.710.29.937.543.542.440.839.98382.179.7828998.7112.5153171.8203.3198.37260.37253.67
0000000000000000000000000
0000.10009.98.89.112.71421.52325.423.829.340.731.129.425.229.632.4232.0137.8
0.140.150.190.30.550.670.710.780.840.930.951.051.251.281.291.291.341.41.431.632.172.483.073.463.77
0.350.390.460.941.041.231.431.641.871.992.222.522.492.612.712.822.973.94.184.625.175.626.418.789.32
                                                 
50.450.450.482.4123.6185.4222.5222.5257.4257.4257.4257.4257.4257.4257.4257.4257.4303.6303.6425595595594.97663.61663.61
0.020.020.020.390.380.360.330.330.590.590.590.590.590.590.590.590.591.21.21.080.910.910.912.692.69
0.080.110.120.170.210.240.30.380.460.610.750.91.011.11.191.271.381.541.742.022.362.753.163.614.18
0000000000000000000000000
0000000000000000000000000
0.150.180.190.650.720.790.850.931.311.451.591.741.851.942.032.122.233.043.253.533.874.264.676.967.53
25.838.932.268.198.3102.693.1155.2125.8139.2158.9221215227.7241.8229.9315.4317.9335.6384.6564505.4721.74695.7765.6
8.114.218.816.81924.326.834.220.17.55.87.19.7104.2718.221.628.443.444.699.369.4551.0864.37
80.482.9108.47169.260.4658994.761.276.9155.328.953.77097.7144.1152.6154.4220.1212210.5174.33174.76201.09
14.117.129.963.2105.1229.5341.1392.4311.5326.7381.9385.9385.6378.6360.1357.9232.4341.3381.4417.3432.2490.4713.93842.09695.53
010547.9018010000001.600000000000
0.130.160.190.270.290.430.530.680.550.530.620.770.640.670.680.690.710.830.91.071.251.311.681.761.73
62.947.965.918180352500000000000000000
00000000000030030000000000000
3.3-4.6001.203.205.3009.15.300025.527.23032.549.76059.9758.9557.62
66.243.365.91819.2038.2255.3009.15.60.30025.527.23032.549.76059.9758.9557.62
0.190.210.260.280.310.430.560.710.560.530.620.780.640.670.680.690.740.860.931.11.31.371.741.821.78
0.350.390.450.931.031.221.411.641.871.992.212.522.492.612.712.812.963.94.184.625.175.626.418.789.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Shandong Pharmaceutical Glass Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Shandong Pharmaceutical Glass Co's financial health and stability.

Assets

Shandong Pharmaceutical Glass Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Shandong Pharmaceutical Glass Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Shandong Pharmaceutical Glass Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Shandong Pharmaceutical Glass Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0000000000000000000000
0000000000000000000000
0000000000000000000000
-32-61-51-59-62-65-88-108-125-146-61-318-355-389-426-503-569-600-667-589-703-779
0000000000000000000000
0000000000000000000000
-64-73-93-97-97-103-130-139-118-137-84-67-109-123-130-137-153-200-83-80-166-137
2810959-344781229124921727428268266389506412465599566750252
-25-112-271-146-85-70-160-158-118-200-217-122-150-133-155-196-167-347-591-535-809-710
-23-109-271-165-99-81-145-154-99-200-182-116-145-166-96-324-457-700-228-286-867-1,488
120-19-14-101541903454-3358-128-290-353363249-57-777
0000000000000000000000
58-1-129410913-1556-220-9960-305-114-28-300000
0000000000000000000000
0.020.37-0.020.070.08-0.030.1-0-0.02-0.01-0.130.03-0.07-0.03-0.160.53-0.06-0.1-0.13-0.18-0.181.67
-0.010.4000-00.290000000.0100.67000001.85
-36-24-10-19-28-36-38-9-21-30-29-30-38-44-45-104-57-100-127-178-178-178
0.150.61-0.030.060.230.220.420.270.620.510.380.360.780.851.091.871.010.951.61.321.321.62
3.3-3.2-212.4-149.8-417.9-38.2-66.6130.916.657.1-93.6118.1133.1234.5309.9244.9118.47.430.8-58.82-458.27
0000000000000000000000

Shandong Pharmaceutical Glass Co stock margins

The Shandong Pharmaceutical Glass Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shandong Pharmaceutical Glass Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shandong Pharmaceutical Glass Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shandong Pharmaceutical Glass Co's sales revenue. A higher gross margin percentage indicates that the Shandong Pharmaceutical Glass Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shandong Pharmaceutical Glass Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shandong Pharmaceutical Glass Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shandong Pharmaceutical Glass Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shandong Pharmaceutical Glass Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shandong Pharmaceutical Glass Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shandong Pharmaceutical Glass Co Margin History

Shandong Pharmaceutical Glass Co Gross marginShandong Pharmaceutical Glass Co Profit marginShandong Pharmaceutical Glass Co EBIT marginShandong Pharmaceutical Glass Co Profit margin
2026e27.44 %19.61 %19.14 %
2025e27.44 %19.69 %18.54 %
2024e27.44 %19.12 %17.72 %
202327.44 %17.17 %15.57 %
202226.28 %16.04 %14.77 %
202128.93 %17.87 %15.25 %
202032.68 %19.6 %16.47 %
201936.44 %17.79 %15.33 %
201835.08 %15.86 %13.86 %
201731.7 %13.34 %11.28 %
201631.51 %13 %9.22 %
201530.51 %11.94 %8.44 %
201425.97 %10.14 %7.37 %
201326.97 %11.38 %7.92 %
201226.69 %11.16 %8.16 %
201126.93 %10.42 %9.48 %
201029.31 %13.69 %11.32 %
200930.3 %14.39 %11.62 %
200827.89 %12.7 %11.67 %
200729.28 %16.29 %11.33 %
200631.83 %17.78 %11.23 %
200533.94 %19.52 %12.27 %
200437.08 %21.21 %13.51 %

Shandong Pharmaceutical Glass Co Stock Sales Revenue, EBIT, Earnings per Share

The Shandong Pharmaceutical Glass Co earnings per share therefore indicates how much revenue Shandong Pharmaceutical Glass Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Shandong Pharmaceutical Glass Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shandong Pharmaceutical Glass Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shandong Pharmaceutical Glass Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shandong Pharmaceutical Glass Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Shandong Pharmaceutical Glass Co Revenue, EBIT and net profit per share

DateShandong Pharmaceutical Glass Co Sales per ShareShandong Pharmaceutical Glass Co EBIT per shareShandong Pharmaceutical Glass Co Earnings per Share
2026e10.77 undefined0 undefined2.06 undefined
2025e9.69 undefined0 undefined1.8 undefined
2024e8.56 undefined0 undefined1.52 undefined
20237.51 undefined1.29 undefined1.17 undefined
20226.31 undefined1.01 undefined0.93 undefined
20216.51 undefined1.16 undefined0.99 undefined
20205.76 undefined1.13 undefined0.95 undefined
20195.03 undefined0.89 undefined0.77 undefined
20184.34 undefined0.69 undefined0.6 undefined
20173.92 undefined0.52 undefined0.44 undefined
20164.1 undefined0.53 undefined0.38 undefined
20153.42 undefined0.41 undefined0.29 undefined
20143.35 undefined0.34 undefined0.25 undefined
20133.06 undefined0.35 undefined0.24 undefined
20122.91 undefined0.32 undefined0.24 undefined
20112.77 undefined0.29 undefined0.26 undefined
20103 undefined0.41 undefined0.34 undefined
20092.46 undefined0.35 undefined0.29 undefined
20082.3 undefined0.29 undefined0.27 undefined
20072.05 undefined0.33 undefined0.23 undefined
20061.96 undefined0.35 undefined0.22 undefined
20051.54 undefined0.3 undefined0.19 undefined
20041.28 undefined0.27 undefined0.17 undefined

Shandong Pharmaceutical Glass Co business model

Shandong Pharmaceutical Glass Co is one of the most popular companies on Eulerpool.com.

Shandong Pharmaceutical Glass Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Shandong Pharmaceutical Glass Co historical P/E ratio, EBIT multiple, and P/S ratio

Shandong Pharmaceutical Glass Co shares outstanding

The number of shares was Shandong Pharmaceutical Glass Co in 2023 — This indicates how many shares 663.614 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Shandong Pharmaceutical Glass Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shandong Pharmaceutical Glass Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shandong Pharmaceutical Glass Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shandong Pharmaceutical Glass Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Shandong Pharmaceutical Glass Co stock splits

In Shandong Pharmaceutical Glass Co's history, there have been no stock splits.

Shandong Pharmaceutical Glass Co dividend history and estimates

In 2023, Shandong Pharmaceutical Glass Co paid a dividend amounting to 0.3 CNY. Dividend means that Shandong Pharmaceutical Glass Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Shandong Pharmaceutical Glass Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Shandong Pharmaceutical Glass Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Shandong Pharmaceutical Glass Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Shandong Pharmaceutical Glass Co Dividend History

DateShandong Pharmaceutical Glass Co Dividend
2026e0.32 undefined
2025e0.32 undefined
2024e0.32 undefined
20230.3 undefined
20220.3 undefined
20210.3 undefined
20200.3 undefined
20190.21 undefined
20180.15 undefined
20170.1 undefined
20160.09 undefined
20150.08 undefined
20140.08 undefined
20130.07 undefined
20120.05 undefined
20110.05 undefined
20100.05 undefined
20090.03 undefined
20070.05 undefined
20060.05 undefined
20050.05 undefined
20040.04 undefined

Shandong Pharmaceutical Glass Co dividend payout ratio

In 2023, Shandong Pharmaceutical Glass Co had a payout ratio of 31.33%. The payout ratio indicates the percentage of the company's profits that Shandong Pharmaceutical Glass Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Shandong Pharmaceutical Glass Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Shandong Pharmaceutical Glass Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Shandong Pharmaceutical Glass Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Shandong Pharmaceutical Glass Co Payout Ratio History

DateShandong Pharmaceutical Glass Co Payout ratio
2026e31.38 %
2025e31.59 %
2024e31.24 %
202331.33 %
202232.2 %
202130.2 %
202031.58 %
201927.83 %
201825.52 %
201723.18 %
201622.82 %
201526.38 %
201430.6 %
201329.75 %
201221.25 %
201119.62 %
201015 %
200910.55 %
200831.33 %
200723 %
200623.18 %
200526.84 %
200425 %
Unfortunately, there are currently no price targets and forecasts available for Shandong Pharmaceutical Glass Co.

Shandong Pharmaceutical Glass Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.36 0.39  (6.16 %)2024 Q2
3/31/20240.28 0.33  (16.69 %)2024 Q1
12/31/20230.28 0.24  (-13.91 %)2023 Q4
9/30/20230.32 0.35  (8.42 %)2023 Q3
6/30/20230.27 0.33  (23.27 %)2023 Q2
3/31/20230.29 0.25  (-13.16 %)2023 Q1
12/31/20220.28 0.2  (-29.99 %)2022 Q4
9/30/20220.3 0.29  (-3.96 %)2022 Q3
6/30/20220.3 0.28  (-7.26 %)2022 Q2
3/31/20220.29 0.26  (-12.09 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Shandong Pharmaceutical Glass Co stock

Eulerpool World ESG Rating (EESG©)

9/ 100

🌱 Environment

10

👫 Social

12

🏛️ Governance

5

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Shandong Pharmaceutical Glass Co shareholders

%
Name
Stocks
Change
Date
2.56295 % Hwabao WP Fund Management Co., Ltd.17,008,0743,392,4789/30/2023
19.49642 % Shandong Luzhong Investment Co., Ltd.129,380,98009/30/2023
1.90848 % T. Rowe Price Associates, Inc.12,664,972-4003/31/2024
1.74882 % HuaAn Fund Management Co., Ltd.11,605,3837,528,38312/31/2023
1.36297 % China Universal Asset Management Co., Ltd.9,044,876-598,9009/30/2023
1.26867 % China Southern Asset Management Co. Ltd.8,419,0794,203,77412/31/2023
1.12805 % Lu (Chengbin)7,485,921104,6009/30/2023
0.93820 % GF Fund Management Co., Ltd.6,226,0322,593,9319/30/2023
0.84922 % Harvest Fund Management Co., Ltd.5,635,55009/30/2023
0.82892 % Abu Dhabi Investment Authority5,500,8209009/30/2023
1
2
3
4
5
...
10

Shandong Pharmaceutical Glass Co Executives and Management Board

Mr. Yonggang Hu57
Shandong Pharmaceutical Glass Co Chairman of the Board (since 2020)
Compensation 2.05 M
Mr. Jun Zhang53
Shandong Pharmaceutical Glass Co General Manager, Director (since 2003)
Compensation 1.76 M
Mr. Wansheng He47
Shandong Pharmaceutical Glass Co Deputy General Manager
Compensation 1.59 M
Mr. Xingjun Wang50
Shandong Pharmaceutical Glass Co Deputy General Manager, Director
Compensation 1.45 M
Mr. Gang Chen46
Shandong Pharmaceutical Glass Co Deputy General Manager, Director (since 2022)
Compensation 1.44 M
1
2
3

Shandong Pharmaceutical Glass Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Jiangsu Hengrui Pharmaceuticals A Stock
Jiangsu Hengrui Pharmaceuticals A
SupplierCustomer0,770,780,960,990,610,74
Hunan Nucien Pharm A Stock
Hunan Nucien Pharm A
SupplierCustomer0,610,890,980,940,600,83
General Electric Stock
General Electric
SupplierCustomer0,60-0,570,590,590,51-0,64
Luoxin Pharmaceuticals Gp A Stock
Luoxin Pharmaceuticals Gp A
SupplierCustomer0,550,830,530,790,690,81
Bayer Stock
Bayer
SupplierCustomer0,42-0,70-0,89-0,92-0,74-0,04
Shandong Lukang Pharm A Stock
Shandong Lukang Pharm A
SupplierCustomer0,390,670,330,650,570,87
Sichuan Kelun Pharm A Stock
Sichuan Kelun Pharm A
SupplierCustomer0,230,850,260,780,620,72
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group
SupplierCustomer0,17-0,540,760,220,180,05
Novartis Stock
Novartis
SupplierCustomer0,13-0,60-0,82-0,71-0,44-0,30
Shanghai Fosun Pharm H Stock
Shanghai Fosun Pharm H
SupplierCustomer0,02-0,28-0,090,230,19-0,22
1
2

Most common questions regarding Shandong Pharmaceutical Glass Co

What is the P/E ratio of Shandong Pharmaceutical Glass Co 2024?

The Shandong Pharmaceutical Glass Co P/E ratio is 19.2.

What is the P/S ratio of Shandong Pharmaceutical Glass Co 2024?

The Shandong Pharmaceutical Glass Co P/S ratio is 3.4.

What is the Quality Investing of Shandong Pharmaceutical Glass Co?

The Quality Investing for Shandong Pharmaceutical Glass Co is 8/10.

What is the revenue of Shandong Pharmaceutical Glass Co 2024?

The expected Shandong Pharmaceutical Glass Co revenue is 5.68 B CNY.

How high is the profit of Shandong Pharmaceutical Glass Co 2024?

The expected Shandong Pharmaceutical Glass Co profit is 1.01 B CNY.

What is the business model of Shandong Pharmaceutical Glass Co

No history available for Shandong Pharmaceutical Glass Co.

What is the Shandong Pharmaceutical Glass Co dividend?

Shandong Pharmaceutical Glass Co pays a dividend of 0.3 CNY distributed over payouts per year.

How often does Shandong Pharmaceutical Glass Co pay dividends?

The dividend cannot currently be calculated for Shandong Pharmaceutical Glass Co or the company does not pay out a dividend.

What is the Shandong Pharmaceutical Glass Co ISIN?

The ISIN of Shandong Pharmaceutical Glass Co is CNE000001BG9.

What is the Shandong Pharmaceutical Glass Co ticker?

The ticker of Shandong Pharmaceutical Glass Co is 600529.SS.

How much dividend does Shandong Pharmaceutical Glass Co pay?

Over the past 12 months, Shandong Pharmaceutical Glass Co paid a dividend of 0.3 CNY . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, Shandong Pharmaceutical Glass Co is expected to pay a dividend of 0.32 CNY.

What is the dividend yield of Shandong Pharmaceutical Glass Co?

The current dividend yield of Shandong Pharmaceutical Glass Co is 1.03 %.

When does Shandong Pharmaceutical Glass Co pay dividends?

Shandong Pharmaceutical Glass Co pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Shandong Pharmaceutical Glass Co?

Shandong Pharmaceutical Glass Co paid dividends every year for the past 18 years.

What is the dividend of Shandong Pharmaceutical Glass Co?

For the upcoming 12 months, dividends amounting to 0.32 CNY are expected. This corresponds to a dividend yield of 1.09 %.

In which sector is Shandong Pharmaceutical Glass Co located?

Shandong Pharmaceutical Glass Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shandong Pharmaceutical Glass Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shandong Pharmaceutical Glass Co from 7/5/2024 amounting to 0.4 CNY, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did Shandong Pharmaceutical Glass Co pay the last dividend?

The last dividend was paid out on 7/5/2024.

What was the dividend of Shandong Pharmaceutical Glass Co in the year 2023?

In the year 2023, Shandong Pharmaceutical Glass Co distributed 0.3 CNY as dividends.

In which currency does Shandong Pharmaceutical Glass Co pay out the dividend?

The dividends of Shandong Pharmaceutical Glass Co are distributed in CNY.

All fundamentals about Shandong Pharmaceutical Glass Co

Our stock analysis for Shandong Pharmaceutical Glass Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shandong Pharmaceutical Glass Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.